Uppsala,
Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has earlier announced its intention to start clinical studies with the drug candidate LIB-01 in mid-2023.
As an important part of the preparations for starting clinical trials, Dicot has finalized the procurement process and selects CTC to conduct the phase 1 studies. CTC is a reputable CRO with a track record of over 400 completed studies for both small and large international pharmaceutical companies. CTC has five state-of-the-art clinical research units in Uppsala,
"CTC came out as the strongest candidate in our procurement process, in competition with several international companies. I`m convinced this will be a good collaboration built on high-level competence and great commitment from both parties. Our joint work starts already now in January," says
"We are very excited about the opportunity to collaborate with a local innovative pharmaceutical company like Dicot, and together with them take their candidate LIB-01 into clinical trials for the first time", comments Anders Millerhovf, CEO at CTC.
For further information, please contact:
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/procurement-completed-for-dicot-s-phase-1-studies,c3693119
https://mb.cision.com/Main/17172/3693119/1763491.pdf
(c) 2023 Cision. All rights reserved., source